Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/321788

Lähdeviite

Luotola , K , Jyväkorpi , S , Urtamo , A , Pitkälä , K H , Kivimäki , M & Strandberg , T E 2020 , ' Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. ' , Age and Ageing , vol. 49 , no. 2 , pp. 258-263 . https://doi.org/10.1093/ageing/afz138

Julkaisun nimi: Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.
Tekijä: Luotola, Kari; Jyväkorpi, Satu; Urtamo, Annele; Pitkälä, Kaisu H.; Kivimäki, Mika; Strandberg, Timo E.
Tekijän organisaatio: HUS Heart and Lung Center
Department of Medicine
Clinicum
Department of General Practice and Primary Health Care
HUS Helsinki and Uusimaa Hospital District
HUS Internal Medicine and Rehabilitation
Teachers' Academy
Päiväys: 2020-03
Kieli: eng
Sivumäärä: 6
Kuuluu julkaisusarjaan: Age and Ageing
ISSN: 0002-0729
DOI-tunniste: https://doi.org/10.1093/ageing/afz138
URI: http://hdl.handle.net/10138/321788
Tiivistelmä: BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns. METHODS: in the Helsinki Businessmen Study, men born in 1919-34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued. RESULTS: we compared 259 current statin users (median age 82 years, interquartile range 80-85 years) with 266 non-users (83; 80-86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P < 0.0001) and worse glucose status than non-users (prevalencies of diabetes 19.0% and 9.4%, respectively, P = 0.0008). However, there was no difference in phenotypic frailty (10.7% versus 11.2%, P = 0.27), and statin users had higher plasma prealbumin level than non-users (mean levels 257.9 and 246.3 mg/L, respectively, P = 0.034 adjusted for age, body mass index and C-reactive protein) implying better nutritional status. Despite morbidity difference, age-adjusted 7-year mortality was not different between the two groups (98 and 103 men among users and non-users of statins, respectively, hazard ratio 0.96, 95% confidence interval 0.72-1.30). CONCLUSIONS: our study suggests that male octogenarian statin users preserved resilience and survival despite multimorbidity, and this may be associated with better nutritional status among statin users.
Avainsanat: 3121 General medicine, internal medicine and other clinical medicine
Cholesterol
CARDIOVASCULAR DISEASE
Metabolic
nutrition
PREALBUMIN
Older people
cholesterol
cardiovascular disease
metabolic
nutrition
prealbumin
older people
OLDER-ADULTS
PRIMARY PREVENTION
TRANSTHYRETIN
Vertaisarvioitu: Kyllä
Tekijänoikeustiedot: unspecified
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: acceptedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Statin_Treatment.pdf 235.5KB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot